Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

MLA

Yanhong Deng, et al. “Subcutaneous Envafolimab Monotherapy in Patients with Advanced Defective Mismatch Repair/Microsatellite Instability High Solid Tumors.” Journal of Hematology & Oncology, vol. 14, June 2021. EBSCOhost, https://doi.org/10.1186/s13045-021-01095-1.

APA

Yanhong Deng, Weijian Guo, John Gong, Lin Shen, Jianwei Yang, Silong Xiang, Shukui Qin, Ying Yuan, Ai-Ping Zhou, David T.L. Liu, Weijie Zhang, Ting Xu, Liangjun Zhu, Haolan Lu, & Jian Li. (2021). Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. Journal of Hematology & Oncology, 14. https://doi.org/10.1186/s13045-021-01095-1

Chicago

Yanhong Deng, Weijian Guo, John Gong, Lin Shen, Jianwei Yang, Silong Xiang, Shukui Qin, et al. 2021. “Subcutaneous Envafolimab Monotherapy in Patients with Advanced Defective Mismatch Repair/Microsatellite Instability High Solid Tumors.” Journal of Hematology & Oncology 14 (June). doi:10.1186/s13045-021-01095-1.